Drugs / RLY-2608
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05216432 | Dec 2021 → Apr 2027 expected | Her2-receptor negative breast cancer, PIK3CA-related overgrowth spectrum | Relay Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06789913 | Jun 2025 → Jul 2031 expected | CLOVES syndrome, angioosteohypertrophic syndrome, lymphatic malformation, megalencephaly-capillary malformation-polymicrogyria syndrome +1 | Relay Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06982521 | Aug 2025 → Apr 2028 expected | hormone receptor-positive breast cancer | Relay Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLY-2608 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06789913 ↗ |
| Known as | zovegalisib | “This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and children with PIK3CA...” NCT06789913 ↗ |
| Action | Inhibit | “PI3Kα inhibitor” NCT05216432 ↗ |
| Modality | Small molecule | — CHEMBL6068523 ↗ |
| Route | Oral | “Multiple doses of RLY-2608 for oral administration.” NCT05216432 ↗ |